ProCE Banner Activity

NICHE-3: Phase II Trial of Neoadjuvant Nivolumab + Relatlimab for Locally Advanced dMMR Colon Cancer

Conference Coverage
Slideset

In the phase II NICHE-3 trial, neoadjuvant nivolumab + relatlimab resulted in a 79% pCR rate for patients with locally advanced dMMR colon cancer with no surgical delays.

Released: October 26, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc